Literature DB >> 28611210

HB-EGF regulates Prss56 expression during mouse decidualization via EGFR/ERK/EGR2 signaling pathway.

Jie Liu1,2, Fei Gao2, Yue-Fang Liu1, Hai-Ting Dou1, Jia-Qi Yan1, Zong-Min Fan1, Zeng-Ming Yang3.   

Abstract

Embryo implantation and decidualization are key steps for successful reproduction. Although numerous factors have been identified to be involved in embryo implantation and decidualization, the mechanisms underlying these processes are still unclear. Based on our preliminary data, Prss56, a trypsin-like serine protease, is strongly expressed at implantation site in mouse uterus. However, the expression, regulation and function of Prss56 during early pregnancy are still unknown. In mouse uterus, Prss56 is strongly expressed in the subluminal stromal cells at implantation site on day 5 of pregnancy compared to inter-implantation site. Under delayed implantation, Prss56 expression is undetected. After delayed implantation is activated by estrogen, Prss56 is obviously induced at implantation site. Under artificial decidualization, Prss56 signal is seen at the primary decidual zone at the initial stage of artificial decidualization. When stromal cells are induced for in vitro decidualization, Prss56 expression is significantly elevated. Dtprp expression under in vitro decidualization is suppressed by Prss56 siRNA. In cultured stromal cells, HB-EGF markedly stimulates Prss56 expression through EGFR/ERK pathway. Based on promoter analysis, we also showed that Egr2 is involved in Prss56 regulation by HB-EGF. Collectively, Prss56 expression at implantation site is modulated by HB-EGF/EGFR/ERK signaling pathway and involved in mouse decidualization.
© 2017 Society for Endocrinology.

Entities:  

Keywords:  Prss56; decidualization; endometrium; uterus

Mesh:

Substances:

Year:  2017        PMID: 28611210     DOI: 10.1530/JOE-16-0636

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  2 in total

1.  Glycogen synthase kinase (GSK) 3 in pregnancy and parturition: a systematic review of literature.

Authors:  Narmada Lavu; Lauren Richardson; Elizabeth Bonney; Ramkumar Menon
Journal:  J Matern Fetal Neonatal Med       Date:  2019-01-06

2.  CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.

Authors:  Xiao-Han Tang; Hui Li; Xiu-Shuang Zheng; Mei-Song Lu; Yuan An; Xiao-Lei Zhang
Journal:  Cancer Med       Date:  2019-09-06       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.